Zydus Lifesciences, an innovation-led life sciences company with a strong international presence, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha. This milestone strengthens the company’s growing capabilities in advanced biologics and Immuno-Oncology, while significantly expanding patient access to cutting-edge cancer therapies.
Competitive Pricing to Improve Treatment Affordability
Tishtha will be available in 100 mg and 40 mg dosage strengths, priced at ₹28,950 and ₹13,950, respectively. Notably, these prices are approximately one-fourth of the reference product, substantially improving affordability and reducing the overall financial burden of cancer treatment.
Additionally, the availability of two dosage strengths allows oncologists to optimise dosing and minimise drug wastage, which remains a key determinant of treatment economics in immunotherapy.
Advancing Patient-Centric Immuno-Oncology Care
As reported by Express Healthcare, commenting on the launch, Dr Sharvil P. Patel, Managing Director, Zydus Lifesciences, reaffirmed the company’s commitment to patient access. He emphasised that every patient deserves timely access to affordable and advanced cancer care. With the introduction of Tishtha, Zydus aims to expand access to Immuno-Oncology therapies through a patient-centric approach, while supporting patients with consistent care throughout their treatment journey.
Ensuring Consistency, Affordability, and Reach
Access to modern cancer treatment depends on three critical factors: consistency, affordability, and reach. Reliable availability of checkpoint inhibitors is particularly vital for patients who require therapy over multiple treatment cycles, as interruptions can increase both clinical risk and financial stress.
Developed and manufactured in India, Tishtha ensures long-term supply reliability, enabling patients to continue therapy without disruption. For individuals living with cancer, predictable and sustained access to treatment is essential for achieving optimal outcomes.
Expanding Access to Advanced Cancer Therapies
By introducing Tishtha in India, Zydus Lifesciences significantly broadens access to advanced Immuno-Oncology treatments, reinforcing its commitment to innovation-driven, affordable healthcare solutions. Through this launch, the company continues to play a pivotal role in making high-quality biosimilar immunotherapies accessible to a wider patient population.